Talk:Eculizumab

message: My name is Rosamond Lieberman and I work with W2O Group, a communications agency working with Alexion Pharmaceuticals. I’d like to suggest edits to this page that more accurately reflect the indications for which Alexion’s therapy eculizumab (Soliris®) is approved by the FDA, and I welcome feedback from any editor. I am aware of Wikipedia’s guidelines, including those on WP:COI, WP:IRS, WP:V and WP:NPOV, and I’ll abide by them. My edit suggestions will be restricted to this Talk page, and I will not engage in directly editing this article. 
In October 2017, the U.S. FDA approved Soliris® (eculizumab) for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody-positive. The corporate Wikipedia page for Alexion (here) has been updated to include this information, so I am requesting that the same updates be reflected on the eculizumab page. This is the source that is referenced on the Alexion Wikipedia page for the approval. Additionally, you may find more information on the approval here.
SOLIRIS is a medicine that affects your immune system. SOLIRIS can lower the ability of your immune system to fight infections. SOLIRIS increases your chance of getting serious and life-threatening meningococcal infections. Meningococcal infections may quickly become life-threatening and cause death if not recognized and treated early. Please see full prescribing information here.
For patients taking Soliris, Alexion provides a complimentary, personalized patient support program called OneSource that is tailored to the specific needs of each patient. This information may be beneficial to any patients or caregivers who visit this Wikipedia page looking for information and resources about the therapy. More information on OneSource can be found here. 
Rklieberman (talk) 16:22, 10 December 2018 (UTC)
thread_title:  Indications for Eculizumab 

message: This article has lots of redundancies, details about diseases that might be better placed in the articles on those diseases, and lots of statements about how to manage various possibilities (lots of how-to statements).  I think also that a lot of the statements in here wouldn't make sense to people who don't already have a fairly detailed understanding of the content.  I'm starting to pare down for a more streamlined and reader-friendly version. Wawot1 (talk) 15:40, 8 April 2014 (UTC)
thread_title: Needs thorough copy edit!

message: Consider removal of "This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (April 2013)" Oceanflynn (talk) 22:52, 25 June 2015 (UTC)
replies: text: Thanks Doc James for removing note re: needing additional citations.Oceanflynn (talk) 22:14, 26 June 2015 (UTC)
thread_title: Consider removal of reliable resources required

message: This article says the drug costs $500K CAD/year in Canada, but according to the CBC it is $700K:  http://www.cbc.ca/news/health/u-s-drug-company-sues-canada-for-trying-to-lower-cost-of-700k-a-year-drug-1.3242172  — Preceding unsigned comment added by 207.6.73.123 (talk) 02:53, 25 September 2015 (UTC)
thread_title:  Cost in Canada 

message: The article states, "Although there are much smaller orphan disease populations are the smallest, the cost of per-patient outlays are the largest and are expected to increase with wider use of public subsidies."
I'm almost certain this sentence is ungrammatical, but because I can't figure out what it means, I can't fix it. The meaning should be clarified and the grammar fixed. 72.183.33.22 (talk) 08:57, 27 May 2016 (UTC)
thread_title:  Bad grammar and unclear meaning in sentence